2476-29-1Relevant articles and documents
Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation
Hu, Yun,Yang, Yaqi,Yu, Yanjun,Wen, Gesi,Shang, Nana,Zhuang, Wei,Lu, Dihan,Zhou, Binhua,Liang, Baoxia,Yue, Xin,Li, Feng,Du, Jun,Bu, Xianzhang
, p. 6033 - 6053 (2013/09/02)
Alzheimer's disease (AD) is associated with impaired Aβ degradation in the brain. Enhancing the process of Aβ clearance is an attractive potential AD therapy. Treatment with LXR agonists may reduce Aβ levels in vivo. However, the clinical potential of man
N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES
-
Page/Page column 15-16, (2008/06/13)
The present invention relates to novel N-sulfamoyl-N'-benzopyranpiperidines of general formula (I) and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the prophylaxis and/or treatment and/or prevention and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and its concomitant and/or secondary diseases or conditions.
Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
-
, (2008/06/13)
Novel disubstituted bicyclic heterocycles, of which the following are exemplary: (a) 1-methyl-2-[(4-amidinophenyl)-oxymethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (b) 1-methyl-2-[2-(4-amidinophenyl)-ethyl]-5-[N-(N-(hydroxycarbonylmethyl)-aminocarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (c) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole and (d) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-indole. These are useful for the treatment of thrombotic disease.